WO2018209358A3 - Systemic delivery of polypeptides - Google Patents

Systemic delivery of polypeptides Download PDF

Info

Publication number
WO2018209358A3
WO2018209358A3 PCT/US2018/032597 US2018032597W WO2018209358A3 WO 2018209358 A3 WO2018209358 A3 WO 2018209358A3 US 2018032597 W US2018032597 W US 2018032597W WO 2018209358 A3 WO2018209358 A3 WO 2018209358A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
systemic delivery
skin tissue
recombinant virus
delivering
Prior art date
Application number
PCT/US2018/032597
Other languages
French (fr)
Other versions
WO2018209358A2 (en
Inventor
Denitsa M. MILANOVA
George M. Church
Noah DAVIDSOHN
Carl SCHOELLHAMMER
Robert S. Langer
Anna I. Mandinova
Carlo Giovanni TRAVERSO
Li Li
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Priority to US16/612,632 priority Critical patent/US20200375868A1/en
Publication of WO2018209358A2 publication Critical patent/WO2018209358A2/en
Publication of WO2018209358A3 publication Critical patent/WO2018209358A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/82—Preparation or application process involves sonication or ultrasonication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy
    • A61N2007/0034—Skin treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

A method of delivering a recombinant virus to a skin tissue is provided. The method includes applying ultrasound to the skin tissue, and administering the recombinant virus to the skin tissue.
PCT/US2018/032597 2017-05-12 2018-05-14 Systemic delivery of polypeptides WO2018209358A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/612,632 US20200375868A1 (en) 2017-05-12 2018-05-14 Systemic Delivery of Polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762505359P 2017-05-12 2017-05-12
US62/505,359 2017-05-12

Publications (2)

Publication Number Publication Date
WO2018209358A2 WO2018209358A2 (en) 2018-11-15
WO2018209358A3 true WO2018209358A3 (en) 2018-12-06

Family

ID=64105658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/032597 WO2018209358A2 (en) 2017-05-12 2018-05-14 Systemic delivery of polypeptides

Country Status (2)

Country Link
US (1) US20200375868A1 (en)
WO (1) WO2018209358A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022251923A1 (en) * 2021-06-04 2022-12-08 Centre For Eye Research Australia Ltd Macular telangiectasia type 2 treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084938A1 (en) * 1998-07-13 2006-04-20 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US20100217212A1 (en) * 1997-12-30 2010-08-26 Eppstein Jonathan A Microporation of Tissue for Delivery of Bioactive Agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151717A1 (en) * 2016-03-01 2017-09-08 French Brent A Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100217212A1 (en) * 1997-12-30 2010-08-26 Eppstein Jonathan A Microporation of Tissue for Delivery of Bioactive Agents
US20060084938A1 (en) * 1998-07-13 2006-04-20 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [O] 2 September 2016 (2016-09-02), "Synthetic construct Mus musculus collagen, type I, alpha 1, mRNA (cDNA clone IMAGE:4036918), **** WARNING: chimeric clone ****", XP055553549, retrieved from ncbi Database accession no. BC042642.1 *
DATABASE Nucleotide [O] 26 June 2008 (2008-06-26), "Homo Sapiens Collagen, Type III, Alpha 1, mRNA (cDNA Clone MGC: 39848 IMAGE:5405119), Complete Cds", XP055553545, retrieved from ncbi Database accession no. BC028178.1 *
DELALANDE. A. ET AL.: "Ultrasound And Microbubble-Assisted Gene Delivery: Recent Advances A nd Ongoing Challenges", THERAPEUTIC DELIVERY, vol. 3, no. 10, 23 October 2012 (2012-10-23), pages 1199 - 1215 *

Also Published As

Publication number Publication date
US20200375868A1 (en) 2020-12-03
WO2018209358A2 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
SA518392270B1 (en) Medical ice slurry production and delivery systems and methods
MX2017004708A (en) Treatment of cancer using tlr9 agonist with checkpoint inhibitors.
MX2019003098A (en) Pharmaceutical composition.
EP3697481A4 (en) Nasal drug delivery apparatus and methods of use
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MA40630A (en) Therapeutic agent delivery device with advanceable cannula and needle
WO2019035057A3 (en) Exosomes for target specific delivery and methods for preparing and delivering the same
EP3538187A4 (en) Multimodal surgical gas delivery system configured to maintain stable body cavity pressure when suction is used in the body cavity
TWD192266S (en) Drug infusion device
MX2019010397A (en) Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide.
EP4309640A3 (en) Body ink compositions
WO2015023649A3 (en) Peptides for enhancing transdermal delivery
MX2019009580A (en) Liquid applicator for delivering vaccines.
EP3817747A4 (en) Targeted delivery of therapeutic agents to human adipocytes
WO2018209358A3 (en) Systemic delivery of polypeptides
EP3762022A4 (en) Human papillomavirus vaccines and uses of the same
MX2019005309A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use.
EP3703659A4 (en) Systems, apparatus, and methods for delivery of therapeutic substance to nasal cavity
EP3846884B8 (en) Medicament delivery device and methods
TW201642906A (en) Fixed dose combination for pain relief without edema
EP3735245A4 (en) Nanoparticles for the targeted delivery of therapeutic polypeptides
WO2018236090A3 (en) Chitosan-pluronic complex and nano-carrier comprising same
MX2022001772A (en) Isotretinoin formulations and uses and methods thereof.
MX2018011121A (en) Preventing biological tissue adhesion.
PH12016501500A1 (en) Topical formulations of heparin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18798713

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18798713

Country of ref document: EP

Kind code of ref document: A2